Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023Calendar Year Performance 2024
- 4.9 %
+ 1.3 %
+ 0.3 %
- 16.1 %
+ 9.1 %
+ 27.0 %
- 6.2 %
+ 2.1 %
+ 13.2 %
+ 10.2 %
Net Asset Value
339.97 €
Asset Under Management
134 M €
Net Equity Exposure31/03/2025
8.1 %
SFDR - Fund Classification
Article
8
Data as of: 31 Mar 2025.
Data as of: 17 Apr 2025.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
The US markets had their worst month since December 2022. This decline is mainly attributed to the imminent announcement of new tariffs.
Technology equities have suffered particularly. On the other hand, defensive sectors such as healthcare have performed positively.
European and emerging markets continue to outperform the US. However, they have not been spared by concerns about customs barriers.
Investors increasingly fear a scenario in which the US economy enters a sharp slowdown as inflation accelerates.
Performance commentary
In this context, the fund delivered a negative performance, nevertheless outperforming its reference indicator.
This was mainly due to our positions in US and Taiwanese technology companies (TSMC, Nvidia, Broadcom, Synopsys), which were affected by the downward pressure on the sector as a whole.
Novo Nordisk continued to disappoint, penalized by competition from Eli Lilly, and remains exposed to potential tariffs that could affect its growth in the United States.
Our selection of more defensive healthcare stocks held up well during this period of uncertainty (Cencora, McKesson, Elevance Health, Centene).
The active management of the equities exposure made it possible to limit the impact of downward pressures, with the implementation of hedges on the US equities markets and on the US dollar.
Outlook strategy
With global growth in the hands of unpredictable politicians in the United States, China and Europe, our strategy is based on the analysis of company fundamentals.
In this context, we favor assets such as growth stocks that are less dependent on the economic cycle in the United States, Europe and emerging markets, as well as stocks whose valuations already reflect a high degree of uncertainty.
Despite the high volatility in the technology sector, we are keeping our investments broadly unchanged. While the sector is facing negative noise, we see little change in the fundamentals for the time being.
The Fund's equity exposure has been reduced through the effect of short index and short equity options as the market downturn has accelerated.
We are gradually building exposure to two investment themes: aerospace and defence and electrical equipment.
In this context, we actively manage the fund's exposure to equities.
I always strive to fully exploit the Fund’s dynamic nature. The return of inflation is the return of the economic cycle where truly active management will stand out even more as the recent years have shown.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
The Funds are common funds in contractual form (FCP) conforming to the UCITS Directive under French law except Carmignac Investissement Latitude, alternative investment fund (AIF) under French law.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Unsupported browserWe've noticed that your browser is no longer supported. To ensure optimal performance and security while using our website, we recommend updating your browser or other relevant software. Thank you for your understanding!
Market environment